
Champions Oncology CSBR
$ 5.85
0.0%
Quarterly report 2025-Q4
added 03-12-2026
Champions Oncology Accounts Payables 2011-2026 | CSBR
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Champions Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.25 M | 5.8 M | 5.33 M | 2.87 M | 1.89 M | 3.14 M | 2.81 M | 2.15 M | 1.85 M | 1.9 M | 1.41 M | 981 K | 1.2 M | 1.68 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.8 M | 981 K | 2.66 M |
Quarterly Accounts Payables Champions Oncology
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.73 M | 4.84 M | 4.25 M | - | 4.85 M | 5.24 M | 5.8 M | 4.54 M | 5.76 M | 5.33 M | 3.74 M | 4.6 M | 2.54 M | 2.87 M | 1.74 M | 3.48 M | 3.34 M | 1.89 M | 2.22 M | 3.95 M | 2.68 M | 3.14 M | 2.12 M | 2.79 M | 2.72 M | 2.81 M | 1.96 M | 2.02 M | 2.12 M | 2.15 M | 1.32 M | 1.55 M | 1.73 M | 1.85 M | 1.52 M | 1.15 M | 1.51 M | 1.9 M | 1.36 M | 1.34 M | 1.44 M | 1.41 M | 937 K | 1.63 M | 1.33 M | 981 K | 1.1 M | 982 K | 976 K | 1.2 M | 1.62 M | 1.21 M | 1.29 M | 1.68 M | - | 1.29 M | 1.5 M | 1.58 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.8 M | 937 K | 2.48 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
Aptorum Group Limited
APM
|
3.24 M | $ 0.89 | - | $ 6.54 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
16.2 M | $ 22.35 | 0.68 % | $ 3.7 B | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | ||
|
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
7.07 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
1.76 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.65 | 22.48 % | $ 6.01 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
1.74 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
29.9 M | $ 4.08 | 0.74 % | $ 436 M | ||
|
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
2.31 M | - | 17.91 % | $ 11.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 22.65 | 1.25 % | $ 2.88 B | ||
|
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | ||
|
Athira Pharma
ATHA
|
4.59 M | - | - | $ 269 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
Avenue Therapeutics
ATXI
|
78 K | - | -52.27 % | $ 4.45 M | ||
|
Aileron Therapeutics
ALRN
|
3.98 M | - | 10.36 % | $ 9.8 M | ||
|
Autolus Therapeutics plc
AUTL
|
3.08 M | $ 1.42 | 0.71 % | $ 378 M | ||
|
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
1.74 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M | ||
|
Exelixis
EXEL
|
29.6 M | $ 45.0 | 0.69 % | $ 12.2 B | ||
|
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B |